Steven P. Levine, MD

home / authors / steven-p-levine

Dr Levine is senior vice president of Patient Access and Medical Affairs at Compass Pathways and chairman at Heading Health.

Articles

treatment resistant depression

Defining Treatment-Resistant Depression

May 21st 2023

Does treatment-resistant depression exist? These 2023 APA Annual Meeting panelists discuss definitions in this exclusive video.

Integrated Care and Treatment-Resistant Depression

Integrated Care and Treatment-Resistant Depression

July 15th 2021
Electroconvulsive Therapy for Depression

Electroconvulsive Therapy for Depression

July 15th 2021
Traditional Classes of Antidepressant Therapies

Traditional Classes of Antidepressant Therapies

July 15th 2021
Frontline Psychotherapy for Depression

Frontline Psychotherapy for Depression

July 15th 2021
Treatment-Resistant Depression: Financial Support for Esketamine Therapy

Treatment-Resistant Depression: Financial Support for Esketamine Therapy

July 15th 2021
Incorporating Esketamine into Practice for Treatment-Resistant Depression

Incorporating Esketamine into Practice for Treatment-Resistant Depression

July 15th 2021
Getting Certified to Administer Esketamine for Treatment-Resistant Depression

Getting Certified to Administer Esketamine for Treatment-Resistant Depression

July 15th 2021
Treatment-Resistant Depression: Administering Esketamine to Patients

Treatment-Resistant Depression: Administering Esketamine to Patients

July 15th 2021
REMS Safety Program for Esketamine in Treatment-Resistant Depression

REMS Safety Program for Esketamine in Treatment-Resistant Depression

July 15th 2021
Response to Esketamine Therapy for Treatment-Resistant Depression

Response to Esketamine Therapy for Treatment-Resistant Depression

July 15th 2021
Monitoring Patients on Esketamine Therapy for Treatment-Resistant Depression

Monitoring Patients on Esketamine Therapy for Treatment-Resistant Depression

July 15th 2021
Esketamine for Treatment-Resistant Depression: Patient Selection Criteria

Esketamine for Treatment-Resistant Depression: Patient Selection Criteria

July 15th 2021
Intranasal Esketamine for Treatment-Resistant Depression

Intranasal Esketamine for Treatment-Resistant Depression

July 15th 2021
Current Guidelines for Managing Treatment-Resistant Depression

Current Guidelines for Managing Treatment-Resistant Depression

July 15th 2021
IV Ketamine for Treatment-Resistant Depression

IV Ketamine for Treatment-Resistant Depression

July 15th 2021
Prevalence of Treatment-Resistant Depression

Prevalence of Treatment-Resistant Depression

July 15th 2021
© 2024 MJH Life Sciences

All rights reserved.